Skip to main content
SpringerLink
Log in

Management of Chronic Hepatitis B

Defining the Role of Lamivudine

  • Drugs in Disease Management
  • Published:
Disease Management and Health Outcomes

Abstract

According to the WHO, approximately 350 million people have chronic hepatitis B. Individuals with chronic hepatitis B have a highly variable and unpredictable clinical course and are at risk for developing cirrhosis and hepatocellular carcinoma. Lamivudine is the only oral antiviral agent approved for the treatment of patients with chronic hepatitis B.

Lamivudine is useful in a wide range of patients with chronic hepatitis B and ongoing viral replication. In patients with compensated liver disease treated for 52 weeks in multicenter randomized, double-blind clinical studies, lamivudine 100 mg/day inhibited hepatitis B virus (HBV) replication, normalized ALT levels, produced significant reductions in hepatic necroinflammatory activity and halted the progression of fibrosis compared with placebo. Hepatitis B e antigen (HBeAg) seroconversion rates were also increased during treatment with the drug compared with placebo.

In patients who continued to receive the drug after the completion of these trials, improvements in liver histology were maintained and HBeAg seroconversion rates increased in proportion to the duration of treatment.

Pretreatment ALT levels were predictive of HBeAgseroconversion. In patients with baseline ALT levels ≥2-fold higher than the upper limit of normal, seroconversion rates were significantly higher than in those with lower baseline values.

Data from 2 randomized studies indicate that sequential therapy with lamivudine for 8 weeks and then lamivudine plus interferon-α for 16 weeks provides no greater benefit than that of monotherapy with lamivudine for 52 weeks or interferon-α for 16 weeks.

According to data from noncomparative studies, lamivudine 100 or 150 mg/day resulted in clinical stabilization, significant reductions in Child-Pugh-Turcotte scores and loss of HBeAg in many patients with decompensated liver disease. Moreover, some patients have been placed on inactive status for liver transplantation after treatment with the drug.

Lamivudine-resistant HBV variants have been isolated from patients with chronic hepatitis B during treatment with lamivudine. The prevalence of these variants increases with the duration of treatment; however, their long term clinical significance has not been established.

Lamivudine is well tolerated. The frequency of adverse events in lamivudine or placebo recipients was similar in a pooled analysis of clinical trial data. Nonetheless, patients must be monitored for the emergence of lamivudine-resistant variants and elevated liver enzyme levels (ALT flares).

In a series of economic models, use of lamivudine was predicted to reduce the cost per case of cirrhosis prevented and increase mean life expectancy compared with use of interferon-α in the US. Other analyses, which incorporated a fixed drug budget scenario, concluded that use of lamivudine would increase the number of successfully treated patients by 2- to 3-fold compared with interferon-α, because of lower acquisition costs.

In conclusion, lamivudine is useful in a wide range of patients with chronic hepatitis B and ongoing viral replication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Table IV
Table V

Similar content being viewed by others

Notes

  1. Patients received prednisolone 30 mg/day for 3 weeks, 15 mg/day for 1 week, then no treatment for 2 weeks before starting lamivudine 150 mg/day which was continued for 9 months.

References

  1. Perry CM, Faulds D. Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997 Apr; 53: 657–80

    Article  PubMed  CAS  Google Scholar 

  2. Perry CM, Barman Balfour JA. Management of HIV infection: the potential role of the lamivudine/zidovudine combination formulation. Dis Manage Health Outcomes 1998 Nov; 4(5): 277–93

    Article  Google Scholar 

  3. Jarvis B, Faulds D. Lamivudine: a review of its therapeutic potential in chronic hepatitis B. Drugs 1999 Jul; 58: 101–41

    Article  PubMed  CAS  Google Scholar 

  4. Leung N. Nucleoside analogues in the treatment of chronic hepatitis B. J Gastroenterol Hepatol 2000 May; 15 Suppl.: E53–60

    Article  PubMed  CAS  Google Scholar 

  5. Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996 Nov 1; 125: 705–12

    PubMed  CAS  Google Scholar 

  6. Dore GJ, Cooper DA, Barrett C, et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999 Sep; 180: 607–13

    Article  PubMed  CAS  Google Scholar 

  7. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996 Nov 2; 348: 1212–5

    Article  PubMed  CAS  Google Scholar 

  8. Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996 Nov 27; 62: 1456–62

    Article  PubMed  CAS  Google Scholar 

  9. Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29: 1581–6

    Article  PubMed  CAS  Google Scholar 

  10. Gugenheim J, Baldini E, Ouzan D, et al. Good results of lamivudine in hepatitis B surface antigen-positive patients with active viral replication before liver transplantation. Transplant Proc 1999 Feb–Mar; 31: 554–5

    Article  PubMed  CAS  Google Scholar 

  11. Lo CM, Fan ST, Lai CL, et al. Lamivudine prophylaxis in liver transplantation for hepatitis B in Asians. Transplant Proc 1999 Feb–Mar; 31: 535–6

    Article  PubMed  CAS  Google Scholar 

  12. Nery JR, Weppler D, Rodriguez M, et al. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998 Jun 27; 65: 1615–21

    Article  PubMed  CAS  Google Scholar 

  13. Yao FY, Osorio RW, Roberts JP, et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999 Nov; 5: 491–6

    Article  PubMed  CAS  Google Scholar 

  14. Yoshida EM, Erb SR, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl 1999 Nov; 5: 520–5

    Article  CAS  Google Scholar 

  15. McCaughan GW, Spencer J, Koorey D, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999 Nov; 5: 512–9

    Article  PubMed  CAS  Google Scholar 

  16. Han S-HB, Ofman J, Holt C, et al. An efficacy and costeffectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000 Nov; 6(6): 741–8

    Article  PubMed  CAS  Google Scholar 

  17. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000 Dec; 32(6): 1189–95

    Article  PubMed  CAS  Google Scholar 

  18. Lee WM. Hepatitis B virus infection. N Engl J Med 1997 Dec 11; 337: 1733–45

    Article  PubMed  CAS  Google Scholar 

  19. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994 Sep; 23(3): 437–55

    PubMed  CAS  Google Scholar 

  20. Chu C-M. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000 May; 15 Suppl.: E25–30

    Article  PubMed  Google Scholar 

  21. Lok ASF, Lai C-L, Wu P-C, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92: 1839–43

    PubMed  CAS  Google Scholar 

  22. Imperial JC. Natural history of chronic hepatitis B and C. J Gastroenterol Hepatol 1999 May; 14 Suppl.: 1–5

    Article  Google Scholar 

  23. Anderson MG, Murray-Lyon IM. Natural history of the HBsAg carrier. Gut 1985 Aug; 26: 848–60

    Article  PubMed  CAS  Google Scholar 

  24. Yuen M-F, Lai C-L. Natural history of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2000 May; 15 Suppl.: E20–24

    Article  PubMed  Google Scholar 

  25. Fattovich G, Giustina G, Sanchez-Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998; 93(6): 896–900

    Article  PubMed  CAS  Google Scholar 

  26. Di Marco V, Lo Iacono O, Cammà C, et al. The long-term course of chronic hepatitis B. Hepatology 1999 Jul; 30: 257–64

    Article  PubMed  Google Scholar 

  27. Chun YK, Kim JY, Woo HJ, et al. No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection. Hepatology 2000 Nov; 32(5): 1154–62

    Article  PubMed  CAS  Google Scholar 

  28. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294–8

    Article  PubMed  CAS  Google Scholar 

  29. Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988 May–Jun; 8(3): 493–6

    Article  PubMed  CAS  Google Scholar 

  30. de Jongh FE, Janssen HLA, De Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630–5

    PubMed  Google Scholar 

  31. Kao J-H, Chen P-J, Lai M-Y, et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000 Mar; 118(3): 554–9

    Article  PubMed  CAS  Google Scholar 

  32. Beasley RP. Hepatitis B virus the major etiology of hepatocellular carcinoma. Cancer 1988 May 15; 61(10): 1942–56

    Article  PubMed  CAS  Google Scholar 

  33. Idilman R, De Maria N, Colantoni A, et al. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. J Viral Hepatitis 1998; 5: 285–99

    Article  CAS  Google Scholar 

  34. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745–50

    Article  PubMed  CAS  Google Scholar 

  35. Zuckerman AJ. Prevention of primary liver cancer by immunization. N Engl J Med 1997; 336: 1906–7

    Article  PubMed  CAS  Google Scholar 

  36. Hsieh C-C, Tzonou A, Zavitsanos X, et al. Age at first establishment of chronic hepatitis B virus infection and hepato-cellular carcinoma risk: a birth order study. Am J Epidemiol 1992; 136(9): 1115–21

    PubMed  CAS  Google Scholar 

  37. Ince N, Wands JR. The increasing incidence of hepatocellular carcinoma. N Engl J Med 1999; 340: 798–9

    Article  PubMed  CAS  Google Scholar 

  38. Lee CM, Lu SN, Changchien CS, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999 Oct 1; 86: 1143–50

    Article  PubMed  CAS  Google Scholar 

  39. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001 Jan; 33(1): 62–5

    Article  PubMed  CAS  Google Scholar 

  40. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000; 32: 842–6

    Article  PubMed  CAS  Google Scholar 

  41. Zuckerman AJ. More than third of world’s population has been infected with hepatitis B virus [letter; comment]. BMJ 1999 May 1; 318: 1213

    Article  PubMed  CAS  Google Scholar 

  42. Van Damme P, Vellinga A. Epidemiology of hepatitis B and C in Europe. Acta Gastroenterol Belg 1998 Apr–Jun; 61: 175–82

    PubMed  Google Scholar 

  43. Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board [see comments]. BMJ 1997 Apr 5; 314: 1033–6

    Article  PubMed  Google Scholar 

  44. Torres JR. Hepatitis B and hepatitis delta virus infection in South America. Gut 1996; 38 Suppl. 2: S48–55

    Article  PubMed  Google Scholar 

  45. Lansang MA. Epidemiology and control of hepatitis B infection: a perspective from the Philippines, Asia. Gut 1996; 38 Suppl. 2: S43–7

    Article  PubMed  Google Scholar 

  46. Yao GB. Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut 1996; 38 Suppl. 2: S39–42

    Article  PubMed  Google Scholar 

  47. Kew MC. Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa. Gut 1996; 38 Suppl. 2: S31–6

    Article  PubMed  Google Scholar 

  48. Toukan AU. Hepatitis B in the Middle East: aspects of epidemiology and liver disease after infection. Gut 1996; 38 Suppl. 2: S2–4

    Article  PubMed  Google Scholar 

  49. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996; 38 Suppl. 2: S18–23

    Article  PubMed  Google Scholar 

  50. Guan R. Hepatitis B virus infection in Singapore. Gut 1996; 38 Suppl. 2: S13–7

    Article  PubMed  Google Scholar 

  51. Kiire CF. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Gut 1996; 38 Suppl. 2: S5–12

    Article  PubMed  Google Scholar 

  52. Blakely T, Salmond C, Tobias M. Hepatitis B virus carrier prevalence in New Zealand: population estimates using the 1987 police and customs personnel survey. N Z Med J 1998 Apr 24; 111: 142–4

    PubMed  CAS  Google Scholar 

  53. Prakash C, Sharma RS, Bhatia R, et al. Prevalence in North India of hepatitis B carrier state amongst pregnant women. Southeast Asian J Trop Med Public Health 1998 Mar; 29: 80–4

    PubMed  CAS  Google Scholar 

  54. Pebody RG, Ruutu P, Nohynek H, et al. Changing epidemiology of hepatitis B infection in Finland. Scand J Infect Dis 1999; 31(3): 251–4

    Article  PubMed  CAS  Google Scholar 

  55. Dutra Souto FJ, Fernandes Fontes CJ, Coimbra Gaspar AM, et al. Hepatitis B virus infection in immigrants to the southern Brazilian Amazon. Trans R Soc Trop Med Hyg 1998 May–Jun; 92: 282–4

    Article  Google Scholar 

  56. Roure C. Overview of epidemiology and disease burden of hepatitis B in the European region. Vaccine 1995; 13 Suppl. 1: S18–21

    PubMed  Google Scholar 

  57. McQuillan GM, Coleman PJ, Kruszon-Moran D, et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999 Jan; 89(1): 14–8

    Article  PubMed  CAS  Google Scholar 

  58. Coleman PJ, McQuillan GM, Moyer LA, et al. Incidence of hepatitis B virus infection in the United States, 1976–1994: estimates from the National Health and Nutrition Examination Surveys. J Infect Dis 1998 Oct; 178: 954–9

    Article  PubMed  CAS  Google Scholar 

  59. Wong JB. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness. Acta Gastroenterol Belg 1998 Apr–Jun; 61: 238–42

    PubMed  CAS  Google Scholar 

  60. Wong JB, Koff RS, Tinè F, et al. Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664–75

    PubMed  CAS  Google Scholar 

  61. Metcalf M, Brown N, Peterson S, et al. Health care costs associated with chronic hepatitis B. Am J Health System Pharm 1999 Feb 1; 56: 232–6

    CAS  Google Scholar 

  62. Yang B-M, Paik S-W, Hahn O-S, et al. Direct and indirect cost of hepatitis B in Korea [abstract no. 759]. Hepatology 1999 Oct; 30 (4 Pt 2): 350A

    Google Scholar 

  63. Haiderali AM, Villa K, Schrammel P. Cost-effectiveness of lamivudine for the treatment of chronic hepatitis B in Canada [abstract]. Hepatology 1999 Oct; 30 (4 Pt 2): 347A

    Google Scholar 

  64. Miller DW, Chatterton ML. An economic evaluation of lamivudine for the treatment of chronic hepatitis B infection in China [abstract no. 2437]. Hepatology 1998 Oct; 28 (4 Pt 2) Suppl.: 772A

    Google Scholar 

  65. Lau GKK, Cheung R, Payne SL, et al. Cost-effectiveness of one-year treatment with lamivudine (Zeffix) or a single course of A-interferon in chronic hepatitis B [abstract no. 1720]. Hepatology 2000 Oct; 32 (4 Pt 2): 589A

    Article  Google Scholar 

  66. From the Centers for Disease Control and Prevention. Update: recommendations to prevent hepatitis B virus transmission—United States. JAMA 1999 Mar 3; 281: 790

    Article  Google Scholar 

  67. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999 Apr; 12: 351

    PubMed  CAS  Google Scholar 

  68. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. J Gastroenterol Hepatol 2000 Aug; 15(8): 825–41

    Article  Google Scholar 

  69. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997 Jan 16; 336: 196–203

    Article  PubMed  CAS  Google Scholar 

  70. Vryheid RE, Kane MA, Muller N, et al. Infant and adolescent hepatitis B immunization up to 1999: a global overview. Vaccine 2001; 19: 1026–37

    Article  Google Scholar 

  71. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996 Sep 18; 276(11): 906–8

    Article  PubMed  CAS  Google Scholar 

  72. Chang M-H, Chen C-J, Lai M-S, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997 Jun 26; 336(26): 1855–9

    Article  PubMed  CAS  Google Scholar 

  73. Chang M-H, Shau W-Y, Chen C-J, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 2000 Dec 20; 284(23): 3040–2

    Article  PubMed  CAS  Google Scholar 

  74. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997 Jan 30; 336: 347–56

    Article  PubMed  CAS  Google Scholar 

  75. Glaxo Wellcome Inc. Epivir-HBV (lamivudine) product information. Glaxo Wellcome Inc. Research Triangle Park, NC, USA, Apr 2000

  76. Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, interferon alfa, and depression. Hepatology 2000 Jun; 31(6): 1207–11

    Article  PubMed  CAS  Google Scholar 

  77. Guan R. Interferon monotherapy in chronic hepatitis B. J Gastroenterol Hepatol 2000 May; 15 Suppl.: E34–40

    Article  PubMed  CAS  Google Scholar 

  78. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38–47

    Article  PubMed  CAS  Google Scholar 

  79. Sokal EM, Roberts EA, Mieli-Vergani G, et al. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother 2000 Mar; 44: 590–7

    Article  PubMed  CAS  Google Scholar 

  80. Lok ASF, Ghany MG, Watson G, et al. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepatitis 1998; 5: 171–8

    Article  CAS  Google Scholar 

  81. Malik AH, Lee WM. Hepatitis B therapy: the plot thickens [editorial]. Hepatology 1999 Aug; 30(2): 579–81

    Article  PubMed  CAS  Google Scholar 

  82. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990 Aug 2; 323(5): 295–301

    Article  PubMed  CAS  Google Scholar 

  83. Krogsgaard K, Bindslev N, Christensen E, et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. J Hepatol 1994; 21: 646–55

    Article  PubMed  CAS  Google Scholar 

  84. Erhardt A, Reineke U, Blondin D, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31: 716–25

    Article  PubMed  CAS  Google Scholar 

  85. Wong DKH, Cheung AM, O’Rourke K, et al. Effect of alphainterferon treatment in patients with hepatitis B e antigenpositive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119: 312–23

    PubMed  CAS  Google Scholar 

  86. Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991 Apr 15; 114(8): 629–34

    PubMed  CAS  Google Scholar 

  87. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422–7

    Article  PubMed  CAS  Google Scholar 

  88. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997 Nov; 113(5): 1660–7

    Article  PubMed  CAS  Google Scholar 

  89. Brook MG, Petrovic L, McDonald JA, et al. Histological improvement after anti-viral treatment for chronic hepatitis B virus infection. J Hepatol 1989; 8: 218–25

    Article  PubMed  CAS  Google Scholar 

  90. Hoofnagle JH, Di Bisceglie A, Waggoner JG, et al. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993 Apr; 104(4): 1116–21

    PubMed  CAS  Google Scholar 

  91. Alberti A, Fattovich G. Interferon therapy for the anti-HBe positive form of chronic hepatitis B. Antiviral Res 1994 Jul; 24(2–3): 145–53

    Article  PubMed  CAS  Google Scholar 

  92. Brunetto MR, Giarin M, Saracco G, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993; 105: 845–50

    PubMed  CAS  Google Scholar 

  93. Hunt CM, McGill JM, Allen MI, et al. Clinical relevance of hepatitis B viral mutations. Hepatology 2000 May; 31(5): 1037–44

    Article  PubMed  CAS  Google Scholar 

  94. Rossana M, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10(2): 198–202

    Article  Google Scholar 

  95. Guptan RKC, Thakur V, Malhotra V, et al. Low-dose recombinant interferon therapy in anti-HBe-positive chronic hepatitis B in Asian Indians. J Gastroenterol Hepatol 1998; 13: 675–9

    Article  PubMed  CAS  Google Scholar 

  96. Lai C-L, Chien R-N, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339(2): 61–8

    Article  PubMed  CAS  Google Scholar 

  97. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999 Oct 21; 341: 1256–63

    Article  PubMed  CAS  Google Scholar 

  98. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889–96

    Article  PubMed  CAS  Google Scholar 

  99. British National Formulary. Lamivudine. No. 40. London: The Pharmaceutical Press, 2000 Sep: 293

  100. Johnson MA, Moore KHP, Yuen GJ, et al. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999; 36: 41–66

    Article  PubMed  CAS  Google Scholar 

  101. Dienstag JL, Lai CL, Hann HWL, et al. Natural history and lamivudine response in Asians versus Westerners with chronic hepatitis B [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco, 446

    Google Scholar 

  102. Schiff E, Karayalcin S, Grimm I, et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy [abstract no. 901]. Hepatology 1998 Oct; 28 (4 Pt 2): 388a

    Google Scholar 

  103. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562–8

    Article  PubMed  CAS  Google Scholar 

  104. Suzuki Y, Kumada H, Ikeda K, et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999; 30: 743–8

    Article  PubMed  CAS  Google Scholar 

  105. Leung N, Wu PC, Tsang S, et al. Continued histological improvement in Chinese patients with chronic hepatitis B with 2 years lamivudine [abstract no. 1307]. Hepatology 1998 Oct; 28 (4 Pt 2): 489A

    Google Scholar 

  106. Schiff ER, Heathcote J, Dienstag JL, et al. Improvements in liver histology and cirrhosis with extended lamivudine therapy [abstract no. 546]. Hepatology 2000 Oct; 32 (4 Pt 2): 296A

    Google Scholar 

  107. Tassopoulos NC, Anagnostopoulos GD, Delladetsima JK, et al. Extended lamivudine treatment in patients with HBeAg negative/HBVDNA positive chronic hepatitis B (CHB) [abstract no. 1187]. Hepatology 2000 Oct; 32 (4 Pt 2): 456

    Google Scholar 

  108. Liaw Y-F, Leung NWY, Chang T-T, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000 Jul; 119(1): 172–80

    Article  PubMed  CAS  Google Scholar 

  109. Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000 Feb; 32: 300–6

    Article  PubMed  CAS  Google Scholar 

  110. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen—negative chronic hepatitis B. Hepatology 2000 Oct; 32(4): 847–51

    Article  PubMed  CAS  Google Scholar 

  111. Leung NWY, Lai CL, Chang TT, et al. Three year lamivudine therapy in chronic HBV [abstract no. GS5/25]. J Hepatol 1999; 30 Suppl. 1: 59

    Google Scholar 

  112. Chang TT, Lai CL, Liaw YF, et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years [abstract no. 077]. Antiviral Ther 2000; 5 Suppl. 1: 44

    Google Scholar 

  113. Schiff E, Cianciara J, Kowdley K, et al. Durability of HBeAG seroconversion after lamivudine monotherapy in controlled phase II and III trials [abstract no. 1]. Hepatology 1998 Oct; 28 (4 Pt 2): 163A

    Google Scholar 

  114. Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999 Oct; 30: 1082–7

    Article  PubMed  CAS  Google Scholar 

  115. Guan R, Liaw YF, Leung NWY, et al. Durable HBeAg response in Chinese patients treated with lamivudine [abstract no. PP-2]. J Gastroenterol Hepatol 2000 Sep; 15 Suppl.: I106

    Article  Google Scholar 

  116. Hong SP, Han K-H, Ahn SH, et al. Long-term effect of lamivudine treatment in patients with chronic hepatitis B: efficacy and durability of response after cessation of treatment [abstract no. 1712]. Hepatology 2000 Oct; 32 (4 Pt 2): 587A

    Article  Google Scholar 

  117. Schiff ER, Cianciara J, Willems B, et al. Durability of HBeAG responses to lamivudine and interferon in the early post-treatment period in adults with chronic hepatitis B [abstract no. 872]. Hepatology 2000 Oct; 32 (4 Pt 2): 377A

    Google Scholar 

  118. Schiff E, Cianciara J, Karayalcin S, et al. Durable HBeAg and HBsAg seroconversions after lamivudine for chronic hepatitis B (CHB) [abstract no. P/C06/12]. J Hepatol 2000; 32 Suppl. 2: 99

    Article  Google Scholar 

  119. Song B-C, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000 Oct; 32(4): 803–6

    Article  PubMed  CAS  Google Scholar 

  120. Chien R-N, Liaw Y-F, Atkins M, et al. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999 Sep; 30: 770–4

    Article  PubMed  CAS  Google Scholar 

  121. Chang T-T, Lai CL, Liaw Y-F, et al. Enhanced HBEAG Seroconversion rates in Chinese patients on lamivudine [abstract no. 1038]. Hepatology 1999 Oct; 30 (4 Pt 2): 420A

    Google Scholar 

  122. Liaw Y-F, Tsai S-L, Chien R-N, et al. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000 Sep; 32(3): 604–9

    Article  PubMed  CAS  Google Scholar 

  123. Perrillo RP. Short-term corticosteroid therapy in combination with lamivudine: a case of déjà vu? [Editorial]. Hepatology 2000 Sep; 32(3): 663–5

    Article  PubMed  CAS  Google Scholar 

  124. Villeneuve J-P, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000 Jan; 31: 207–10

    Article  PubMed  CAS  Google Scholar 

  125. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 301–7

    Article  PubMed  CAS  Google Scholar 

  126. Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33: 308–12

    Article  PubMed  CAS  Google Scholar 

  127. Sponseller CA, Bacon BR, Di Bisceglie AM. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. Liver Transpl 2000 Nov; 6(6): 715–20

    Article  PubMed  CAS  Google Scholar 

  128. Yao FYK, Terrault NA, Friese CE, et al. Lamivudine reduces the need for liver transplantation and improves survival in patients with severely decompensated cirrhosis due to active hepatitis B infection: a controlled study [abstract no. 1190]. Hepatology 2000 Oct; 32 (4 Pt 2): 457A

    Google Scholar 

  129. Lampertico P, Iavarone M, Romeo R, et al. Long-term lamivudine therapy improves Child-Pugh score in patients with hepatitis B-related cirrhosis [abstract no. 1195]. Hepatology 2000 Oct; 32 (4 Pt 2): 457

    Google Scholar 

  130. Hann H-WL, Fontana RJ, Wright T, et al. Lamivudinetreatment for decompensated cirrhosis due to hepatitis B: a multicenter longitudinal study [abstract no. 2347]. Gastroenterology 2000 Apr; 118 (4 Pt 1): A1004

    Article  Google Scholar 

  131. Angelico M, Di Paulo D, Palmieri G, et al. Lamivudine improves the Child-Pugh score in HbsAg positive patients listed for transplantation: a single center experience [abstract no. P/C06/31]. J Hepatol 2000; 32 Suppl. 2: 104

    Article  Google Scholar 

  132. Gao BJ, Xie HS, Lu Z. Lamivudine therapy of decompensated chronic hepatitis B [abstract no. P-H-2]. J Gastroenterol Hepatol 2000 Sep; 15 Suppl: I184

    Google Scholar 

  133. Fontana R, Hann H-W, Wright T, et al. Lamivudine treatment of chronic hepatitis B liver transplant candidates: a multi-centre, prospective US study [abstract no. 058]. 10th International Symposium on Viral Hepatitis and Liver Disease; 2000 Apr 9–13; Atlanta, 33

    Google Scholar 

  134. Lim SG, Lo SK, Chong J, et al. Outcome of treatment with lamivudine for chronic hepatitis B in a compassionate care program in Asia [abstract]. Hepatology 1999 Oct; 30 (4 Pt 2): 643

    Google Scholar 

  135. Perrillo RP, Wright T, Rakela J, et al. A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001 Feb; 33(2): 424–32

    Article  PubMed  CAS  Google Scholar 

  136. Jung SA, Chung Y-H, Yang SH, et al. Efficacy and safety of lamivudine therapy in patients with decompensated liver cirrhosis caused by HBV infection [abstract]. Hepatology 1999 Oct; 30 (4 Pt 2): 645A

    Google Scholar 

  137. Fontana RJ, Lok ASF. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when? J Hepatol 2000 (33): 329–32

    Article  PubMed  CAS  Google Scholar 

  138. Fontana RJ, Keeffe EB, Soldevila C, et al. Is lamivudine beneficial in HBsAG+ patients awaiting liver transplantation? Experience in 182 North American patients [abstract no. 40]. Transplantation 1999 Apr 15; 67: S16

    Article  Google Scholar 

  139. Fontana RJ, Perrillo R, Hann H-WL, et al. Determinants of survival in 133 patients with decompensated chronic hepatitis B treated with lamivudine [abstract no. 239]. Hepatology 2000 Oct; 32 (4 Pt 2): 221A

    Google Scholar 

  140. Cotrina M, Buti M, Jardi R, et al. Prediction of long-term response to lamivudine by measuring HBV-DNA levels at month 3 in patients with chronic hepatitis B [abstract no. 1711]. Hepatology 2000 Oct; 32 (4 Pt 2): 587A

    Article  Google Scholar 

  141. Lau DT-Y, Khokhar F, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000 Oct; 32: 828–34

    Article  PubMed  CAS  Google Scholar 

  142. Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001 Feb; 107(4): 449–55

    Article  PubMed  CAS  Google Scholar 

  143. Liaw Y-F, Chien R-N, Yeh C-T, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy [see comments]. Hepatology 1999 Aug; 30: 567–72

    Article  PubMed  CAS  Google Scholar 

  144. Chang TT, Lai CL, Ng KY, et al. Enhanced HBeAg and ALT responses during long term lamivudine treatment in Chinese patients [abstract no. O-H-21]. J Gastroenterol Hepatol 2000 Sep; 15 Suppl.: I134

    Article  Google Scholar 

  145. Lok AS-F, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigennegative patients receiving lamivudine therapy. Hepatology 2000 Nov; 32(5): 1145–53

    Article  PubMed  CAS  Google Scholar 

  146. Lok ASF. Lamivudine therapy for chronic hepatitis B: is longer duration of treatment better? [editorial]. Gastroenterology 2000 Jul; 119(1): 263–6

    Article  PubMed  CAS  Google Scholar 

  147. Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the final solution? [editorial]. Hepatology 2000 Aug; 32(2): 430–2

    Article  PubMed  CAS  Google Scholar 

  148. Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the path forward? Drugs 2000 Sep; 60(3): 517–31

    Article  PubMed  CAS  Google Scholar 

  149. Honkoop P, de Man RA, Niesters HGM, et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000 Sep; 32(3): 635–9

    Article  PubMed  CAS  Google Scholar 

  150. Crowley SJ, Tognarini D, Desmond P. The cost-effectiveness of the introduction of lamivudine for the treatment of chronic hepatitis B in Australia [abstract]. Hepatology 1999 Oct; 30 (4 Pt 2): 181A

    Google Scholar 

  151. Desmond P, Tognarini D, Crowley SJ. The potential impact of lamivudine (100 mg) on the clinical management of chronic hepatitis B in Australia [abstract]. Hepatology 1999 Oct; 30 (4 Pt 2): 643A

    Google Scholar 

  152. Bonzanini A, Gianfrate F, Lloyd A, et al. Adrug budget perspective of lamivudine compared with interferon-α in the treatment of precore chronic hepatitis B in Italy [abstract no. P/C06/49]. J Hepatol 2000; 32 Suppl. 2: 109

    Article  Google Scholar 

  153. Zacks SL, Fried MW. Cost comparison of interferon and lamivudine for the treatment of chronic hepatitis B [abstract no. 1289]. Hepatology 1999 Oct; 30 (4 Pt 2) Suppl.: 483A

    Google Scholar 

  154. Lacey LF, Cox FM, Payne SL. A drug budget perspective of lamivudine compared with interferon-α in the treatment of chronic hepatitis B in the United States [abstract]. Hepatology 1999 Oct; 30 (4 Pt 2): 481A

    Google Scholar 

  155. Dickens T, Raasch RH, Saal GB, et al. The long-term cost-effectiveness of lamivudine for the treatment of chronic hepatitis B in the United States [abstract no. 1722]. Hepatology 2000 Oct; 32 (4 Pt 2): 590A

    Google Scholar 

  156. Dickens T, Raasch RH, Saal GB, et al. The short-term costeffectiveness of lamivudine for the treatment of chronic hepatitis B in the United States [abstract no. 1721]. Hepatology 2000 Sep; 32 (4 Pt 2): 590A

    Google Scholar 

  157. Lau GKK, Tsiang M, Hou J, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis Binfected Chinese patients: a viral dynamics study. Hepatology 2000 Aug; 32(2): 394–9

    Article  PubMed  CAS  Google Scholar 

  158. Kwo PY, Chalasani N, Lumeng L, et al. A pilot study with lamivudine and famciclovir for the treatment of chronic hepatitis B [abstract no. 1717]. Hepatology 2000 Oct; 32 (4 Pt 2): 589

    Google Scholar 

  159. Naoumov NV, Suri D, Rigopoulou EI, et al. Combination treatment with lamivudine plus interleukin-12 shows greater antiviral activity in chronic hepatitis B [abstract no. 868]. Hepatology 2000 Oct; 32 (4 Pt 2): 376

    Google Scholar 

  160. Lin BL, Yang SY, Huang GU, et al. A study on the short-term efficacy of thymosin α1 (Tα1) combined with lamivudine in treating patients with chronic hepatitis B [abstract no. O-H-20]. J Gastroenterol Hepatol 2000 Sep; 15 Suppl.: I133

    Article  Google Scholar 

  161. Farrell GC. Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities for prevention and exploitation? [editorial]. J Gastroenterol Hepatol 1999; 14: 741–4

    Article  PubMed  CAS  Google Scholar 

  162. Pianko S, McHutchison J. Chronic hepatitis B: new therapies on the horizon? [commentary]. Lancet 1999 Nov 13; 354: 1662–3

    Article  PubMed  CAS  Google Scholar 

  163. Farrell GC. Clinical potential of emerging new agents in hepatitis B. Drugs 2000 Oct; 60(4): 701–10

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Blair Jarvis & Caroline M. Perry

Authors
  1. Blair Jarvis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline M. Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Blair Jarvis.

Additional information

Various sections of the manuscript reviewed by: P. Andreone, Dipartimento Di Medicina Interna, Cardioangiologia, Epatologia, Universita degli Studi di Bologna, Bologna, Italy; M. Buti, Hepatology Unit, Hospital Clinic, Department of Medicine, Autonomous University of Barcelona, Spain; A.M. Di Bisceglie, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri, USA; S. Fiorino, Dipartimento Di Medicina Interna, Cardioangiologia, Epatologia, Universita degli Studi di Bologna, Bologna, Italy; H-W.L. Hann, Department of Medicine, Division of Gastroenterology & Hepatology, Jefferson Medical College, and Liver Disease Prevention Unit, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA; N. Leung, Department of Medicine, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China; M.I. Merican, Ministry of Health Malaysia, Institute for Medical Research, Jalan Pahang, Kuala Lumpur, Malaysia; S.K. Sarin, Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India; N.C. Tassopoulos, Western Attica General Hospital, Athens, Greece.

Data Selection

Sources: Medical literature published in any language since 1966 on lamivudine, identified using Medline supplemented by AdisBase (a proprietary database of Adis International, Auckland, New Zealand). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: AdisBase search terms were ‘hepatitis-B’ and (‘guideline’ or ‘guideline-utilisation’ or ‘practice-guideline’ or ‘disease-management-programmes’ or ‘treatment-algorithms’ or ‘reviews-on-treatment’ or ‘drug-evaluations’ or ‘epidemiology’ or ‘cost-of-illness’ or ‘pathogenesis’), or ‘lamivudine’ or ‘BCH-189’ or ‘BTC’ or ‘SDDC’ and (‘review’ or ‘clinical-study’). Medline search terms were ‘hepatitis-B and (‘guidelines’ or ‘decision-making’ or ‘health-policy’ or ‘managed-care-programmes’ or ‘epidemiology’ or ‘outcome-assessment-health-care’ or ‘clinical-protocols’ or ‘guideline in pt’ or ‘practice-guideline in pt’), or ‘lamivudine’ or ‘BCH-189’ or ‘SDDC’ or ‘BTC’ and ‘review in pt’. Searches were last updated 5 March, 2001.

Selection: Studies in patients with chronic hepatitis B who received lamivudine. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic, pharmacokinetic, pharmacoeconomic and epidemiological data are also included.

Index terms: chronic hepatitis B, lamivudine, disease management, reviews on treatment.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jarvis, B., Perry, C.M. Management of Chronic Hepatitis B. Dis-Manage-Health-Outcomes 9, 215–234 (2001). https://doi.org/10.2165/00115677-200109040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200109040-00004

Keywords

Search

Navigation